What Is Bicycle Day – The World’s Biggest Psychedelic Holiday?
Last reviewed and updated: June 26, 2026.
Key Takeaways
| Bicycle Day date | April 19, 1943 — Hofmann’s first intentional LSD dose (250 mcg); bicycled home as effects intensified |
| What happened | Intense visuals, altered sense of self and time, initial fear of poisoning; physician confirmed stable vitals; Hofmann recognized the molecule’s significance immediately |
| Cultural significance | Annual global celebration now includes licensed service center events (Oregon), scientific symposia (CIIS San Francisco), European harm reduction gatherings, Hofmann Foundation programming |
| Hofmann’s own view | Consistently believed LSD had major unrealized psychiatric and end-of-life therapeutic potential; called criminalization of research a political, not scientific, decision |
| 2026 status: Definium DT120 | MindMed’s pharmaceutical LSD completed Phase 3 (positive) in 2025, NDA filed — potentially the first approved pharmaceutical LSD product, ~83 years after Bicycle Day |
Bicycle Day is an annual “holiday” on April 19 that psychedelic enthusiasts celebrate. However, Bicycle Day is more than just that, as it represents a major event in psychedelic history.
April 19 is the day that the effects of LSD (lysergic acid diethylamide) were discovered by Swiss chemist Albert Hofmann. It was on that date in 1943 that Hofmann experienced LSD for the first time in human history. After taking the psychedelic, he went for a bike ride, testing the drug’s effects on himself.
Unfortunately, Hofmann’s experience that afternoon was not as pleasant as some might imagine. But this did not prevent the scientist from continuing his research into LSD’s therapeutic properties.
In the decades to follow, Hoffman’s research remains influential on culture, politics and science.
Here’s a Timeline of Albert Hoffman’s Famed Bicycle Day
April 19th, 4:20 PM: Hofmann ingests 250 micrograms of LSD in his laboratory at Sandoz. He chooses this dose, mistakenly believing it to be the minimum required to achieve an effect, not realizing it’s significantly more potent than necessary.
4:50 PM: About 30 minutes after ingestion, Hofmann starts to feel the effects of LSD. He experiences anxiety, visual distortions, symptoms of paralysis, and a sensation of being intoxicated.
5:00 PM: The effects intensify rapidly. Hofmann asks his laboratory assistant to accompany him home, as he feels overwhelmed and unable to continue working. Due to wartime restrictions and the absence of cars, they decide to use bicycles.
During the bicycle ride home: Hofmann’s condition deteriorates further. The journey home is chaotic and challenging due to his altered state of consciousness. He experiences severe anxiety and hallucinations, which he later described as being both terrifying and exhilarating.
After arriving home: Hofmann’s state of distress continues to escalate. He fears he has poisoned himself with the LSD. The symptoms include extreme hallucinations, a distorted sense of space and time, and a feeling of dissociation from his body.
Late afternoon and evening: At home, Hofmann’s doctor is called, but no physical abnormalities are found aside from dilated pupils. Hofmann is put to bed and, despite his ongoing turmoil, eventually begins to enjoy the visual and auditory distortions, describing them as kaleidoscopic and intensely colorful.
The following hours: Hofmann drifts in and out of a state where he is unable to distinguish between reality and his hallucinations. The experience becomes less frightening and more intriguing and enjoyable as time passes.
The next morning (April 20): Hofmann awakens feeling refreshed and with a sense of well-being. The residual effects of the LSD provide him with a new perspective on life and nature, which he describes as a reinvigorated sense of understanding and appreciation.
What Is Bicycle Day? Explaining How It Began
So, what is Bicycle Day? Arguably, the world’s biggest psychedelic holiday, a professor from Northern Illinois University, Thomas Roberts, began celebrating it in 1985. It takes its name from the legendary experiment of 1943, in which Albert Hoffmann took a bike ride after ingesting a large dose of LSD and discovering its hallucinogenic effects.
Since then, Bicycle Day has spread around the world, becoming a celebration recognizing a pivotal point in the history of psychedelic experimentation. Indeed, a new era in chemistry, medicine, culture, arts and philosophy started after that day in which Hofmann made a guinea pig of himself for his own research.
Bicycle Day represents the opening of a doorway to a richer understanding of human consciousness. In the words of Hofmann, LSD is to be a sacred tool that can help its users attain “a deeper, comprehensive reality.”
This potential rapidly drew attention to psychiatrists and neurophysiologists. In fact, throughout the 1950s and 1960s, many researchers in those fields studied the use of LSD to treat schizophrenia, alcoholism, anxiety, depression and other mental health issues.
Many of these trials, unfortunately, were abandoned because of federal prohibitions led by the infamous War on Drugs in the 1960s and 1970s.
Another impact on psychedelic experimentations with LSD? The hippie movement and the cultural revolution of the 1960s. Many artists, musicians, intellectuals and bohemians in those days took LSD for creative use, which greatly impacted the course of cultural history.
However, Hofmann didn’t imagine the impact of his discovery when he started studying LSD in the late 1930s.
Who Is Albert Hofmann?
Albert Hofmann was the first person to synthesize, ingest and study LSD. His research started in 1938, in the pharmaceutical department of Sandoz Laboratories in Basel, Switzerland, while he was studying ergot, a fungus that usually grows on rye, from which he synthesized LSD as a potential stimulant for treating circulatory and respiratory diseases.
At first, he tested the new substance on sedated animals, but he didn’t find interesting results in those experiments. That’s the reason why his research was shelved until five years after, when he decided to continue studying LSD.
On April 16, 1943, Hofmann synthesized a new batch of what we know as “acid” — or “the wonder drug LSD.” While working on that process, he started feeling strange. He decided to interrupt his job and go back home.
Upon arrival, as he points in his memoir LSD – My Problem Child, he “sank into a not unpleasant intoxicated-like condition, characterized by an extremely stimulated imagination.” Therefore, he thought that an accidental contact with the substance might have caused the weird experience. He decided to take a dose to experiment on himself.
Riding A Bike On A Bad Trip
On April 19, he voluntarily took 250 micrograms of LSD — which is a strong dose. By comparison, the Global Drug Survey recommends between 100 and 200 micrograms. Hoffman then realized that “altered perceptions were of the same type as before, only much more intense.”
After suffering speech difficulties, he believed he had poisoned himself, asking his assistant to help him get home.
Due to restrictions of Second World War times prohibiting the use of cars, they took a bicycle ride to Hofmann’s house. While pedaling, the impact of the LSD hit Hofmann’s system. The trip became a nightmare. Per his memoir, Hoffman said it felt as if a demon “had taken possession of my body, mind and soul.”
At home, he was able to relax and fall asleep. The morning after, he woke up feeling himself to be “in excellent physical and mental conditions.”
A “sensation of well-being and renewed life” flowed through him. From his own experience, Hoffman claims that research on LSD would be valuable to pharmacology and medicine. And from his infamous bike ride, Bicycle Day was born.
Thus, he continued his experiments on acid. This set the stage for the psychedelic revolution that would take place more than a decade later.
Related provider: Lake Avenue Wellness
Bicycle Day in 2025 — And the Extraordinary Moment Hofmann Predicted Is Now Arriving
In 2025, Bicycle Day — April 19 — was marked by events on multiple continents in a way that would have been unimaginable even five years ago. Portland, Oregon, which sits at the center of the first functional legal psilocybin market in the US, held its largest annual gathering at a licensed service center: a ceremonial event framing Hofmann’s ride as the moment the modern therapeutic psychedelic movement was born. San Francisco’s California Institute of Integral Studies hosted its long-running Bicycle Day symposium with a lineup that included clinical researchers from UCSF’s Translational Psychedelic Research program. In Europe, the Netherlands (home to legal psilocybin retreats operating in a regulatory gray zone) and the Czech Republic (which has a robust harm reduction community and is pushing for EU-level psychedelic therapy frameworks) both held events. The Hofmann Foundation, established to carry forward Albert Hofmann’s scientific and humanistic legacy, funded educational programming in six countries in 2025. The day has evolved from a countercultural observance into something that straddles celebration and scientific conference — reflecting how the psychedelic field itself has changed.
Albert Hofmann’s own view on what LSD would become. Hofmann, who lived to 102 and died in 2008, was not shy about his belief that LSD had profound unrealized medical potential. He called LSD his “problem child” — the title of his 1979 memoir — but that was an expression of frustration at its cultural misuse, not doubt about its therapeutic value. He repeatedly stated that LSD’s greatest untapped application was in psychiatry: specifically in treating anxiety, addiction, and existential distress, including end-of-life psychological suffering. In his later years, as the first wave of modern psychedelic research began in the early 2000s, Hofmann expressed something close to vindication — that the scientific community was finally testing the hypotheses he had held for decades. He corresponded with researchers at Johns Hopkins and NYU and donated to early psilocybin research. His 100th birthday in 2006 included a scientific symposium in Basel, Switzerland, attended by researchers who would go on to lead the current generation of psychedelic clinical trials.
The 83-year arc: from bicycle ride to Phase 3 approval. In June 2025 — approximately 82 years after Hofmann’s April 19, 1943 ride — MindMed announced positive Phase 3 results for MM120 (now branded Definium DT120), their pharmaceutical-grade LSD tartrate formulation, for generalized anxiety disorder. The topline results showed statistically significant and clinically meaningful reduction in anxiety symptoms at 12 weeks, meeting the primary endpoint. A New Drug Application was submitted to the FDA, and the compound entered the standard review process. If approved, Definium DT120 would be the first pharmaceutical LSD product in history — something Hofmann predicted was both possible and medically necessary. The timing is extraordinary: the same molecule Hofmann synthesized in 1938 and first experienced in 1943 is, within the span of a single human lifetime, moving from a bicycle commute into a package insert. That this is happening in 2025–2026, rather than the 1970s when LSD research was abruptly shut down by the Controlled Substances Act scheduling, underscores how much of the intervening five decades was regulatory delay rather than scientific uncertainty.
What Hofmann’s prediction means for the psychedelic medicine moment. Hofmann was not simply a chemist — he was an articulate advocate for a specific vision: that altered states of consciousness could be used therapeutically under appropriate conditions, and that the Western medical tradition’s rejection of that possibility was a cultural failure rather than a scientific conclusion. His 2006 Basel birthday symposium produced a document, the “Basel Problem Child Declaration,” calling for the resumption of LSD and psychedelic research under scientific conditions. Nearly 20 years later, the clinical trial infrastructure he was calling for exists. Psilocybin is in Phase 3 trials (Compass Pathways COMP360 for treatment-resistant depression). MDMA-assisted therapy is in re-trial after the FDA’s 2024 methodological feedback. Ketamine is publicly reimbursed in Norway. Ibogaine has received breakthrough therapy designation for opioid use disorder. The ecosystem Hofmann envisioned — in which specific psychedelic molecules, rigorously studied, are part of the formal pharmacopoeia — is now being built. Bicycle Day 2026 marks the 83rd anniversary of the ride; it is also the moment his prediction is closest to being verified by the regulatory apparatus he never quite lived to see.
Frequently Asked Questions
What happened on Bicycle Day?
On April 19, 1943, Swiss chemist Albert Hofmann intentionally ingested 250 micrograms of LSD-25 — a compound he had first synthesized five years earlier in 1938 — to investigate the unusual effects he had briefly experienced during accidental exposure three days prior on April 16. As the effects intensified, Hofmann asked his laboratory assistant to accompany him on the bicycle ride home (private cars were restricted during wartime Switzerland). The journey became legendary: Hofmann experienced intense, kaleidoscopic visual hallucinations and profound alterations in his sense of self and time, and initially feared he had poisoned himself. A physician confirmed his vital signs were stable; the effects resolved over several hours, leaving Hofmann with a clear-headed certainty that he had discovered something of extraordinary scientific and medical significance. The April 19 date is commemorated as Bicycle Day, the world’s most widely observed psychedelic holiday.
How is Bicycle Day celebrated today?
Bicycle Day has grown from a countercultural observance — noted primarily in the psychedelic underground from the 1980s onward — into a globally recognized event that now includes both cultural celebrations and scientific programming. In Portland, Oregon, licensed psilocybin service centers have hosted ceremonial events since Oregon’s legal market opened in 2023. San Francisco’s California Institute of Integral Studies holds an annual symposium. European events in the Netherlands, Czech Republic, and Germany attract researchers, therapists, and advocates. The Hofmann Foundation funds educational programming internationally. Online, the day generates substantial activity on harm reduction platforms (DanceSafe, Zendo Project), psychedelic research organizations (MAPS, Usona Institute), and academic institutions with psychedelic research programs. The tone has shifted: it is as much a professional observance for the growing psychedelic medicine field as it is a personal celebration for people who have had meaningful experiences with psychedelics.
Who was Albert Hofmann and what was his view on LSD?
Albert Hofmann (1906–2008) was a Swiss chemist at Sandoz Laboratories who synthesized LSD-25 on November 16, 1938, as part of a systematic program to develop ergot alkaloid derivatives for potential medical use. The compound was initially set aside; Hofmann revisited it in April 1943 and discovered its extraordinary psychoactive properties. His 1979 memoir, LSD: My Problem Child, remains the definitive primary account of LSD’s discovery. Hofmann held a consistent lifelong view that LSD had profound unrealized therapeutic potential, particularly for psychiatry and end-of-life care. He was openly frustrated by the criminalization of LSD research following the countercultural upheaval of the 1960s, which he felt reflected political and social panic rather than scientific judgment. He lived to 102 and in his final years expressed increasing optimism as modern psychedelic research resumed — attending the Basel birthday symposium in 2006 that helped catalyze a new generation of researchers.
Is LSD close to becoming a medicine?
Closer than at any point since LSD research was effectively halted in the early 1970s. MindMed’s Definium DT120 (MM120, a pharmaceutical-grade LSD tartrate formulation) completed Phase 3 trials in 2025 with positive results for generalized anxiety disorder, and a New Drug Application was submitted to the FDA. If the review goes favorably, DT120 would be the first approved pharmaceutical LSD product in history — approved in 2026, roughly 83 years after Hofmann’s bicycle ride. Separately, research programs at Imperial College London, NYU, and other institutions are studying LSD for addiction, depression, and cluster headaches. The regulatory and manufacturing infrastructure now exists for pharmaceutical LSD in a way it did not in 1943 or 1973. The scientific question of whether LSD is medically useful — which Hofmann was confident about — has largely been answered by clinical evidence; the remaining steps are regulatory and commercial, not scientific.
